

EMCREG-INTERNATIONAL MEMBER DISCLOSURE INFORMATION

Important Considerations:

A relationship is "**relevant**" if the relationship or interest relates to the topic in terms of any of the following: the same or similar subject matter or topic; the same, similar or competing drug or device, product or service, intellectual property or asset; a drug or device company or its competitor; or has the reasonable potential to result in financial, professional or other personal gain or loss for you, members of your household or employer.

Please classify each relationship as either "**Modest**" or "**Significant**." A relationship is considered to be "**Significant**" if (a) the person receives \$10,000 or more during any 12 month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10,000 or more of the fair market value of the entity. A relationship is considered to be "**Modest**" if it is less than "**Significant**" under the preceding definition.

1. **Douglas M. Char, MD**
2. **Date: July 25, 2006**
3. **Employment:** Washington University School of Medicine
4. **Research Grants** (includes principal investigator, collaborator or consultant and pending grants as well as grants already received): none currently
Pending – Quintiles (Apex Bioscience)
5. **Other Research Support** (includes receipt of drugs, supplies, equipment or other-in-kind support): none
6. **Speakers Bureaus** (includes speakers bureau, symposia, and expert witness):
Sanofi-Aventis, Scios Inc
7. **Ownership Interest** (includes stock, stock options, partnership, membership or other equity position in an entity regardless of form of the entity, or any option or right to acquire such position, and any rights in any patent or other intellectual property): None
8. **Consultant/Advisory Board:** CRUSADE (Duke CRI)
9. **Other:**